Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Leibniz-Institut Für Virologie maintains a company patent portfolio within the Biotechnology & Pharmaceuticals sector. Currently, the portfolio includes 2 pending office actions. This workload is handled by 2 distinct examiners, including ALLEN, MICHAEL D, who is the busiest examiner with 1 busiest examiner pending action. All prosecution activity is localized within 1 distinct art unit.
For a practitioner, this concentration within 1 distinct art unit means the company's current USPTO engagement follows a consistent technical theme. The 2 pending office actions represent the entirety of the active pipeline. Navigating the Biotechnology & Pharmaceuticals field with 2 distinct examiners allows for a distributed approach to prosecution. However, it also means the portfolio's immediate growth depends on the resolution of the 1 busiest examiner pending action. Practitioners should tailor their strategy specifically to the tendencies of ALLEN, MICHAEL D to optimize outcomes within the 1 distinct art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §103 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEN, MICHAEL D | 1 | 31.9% | +48.8% |
| ZOU, NIANXIANG | 1 | 64.0% | +25.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18007364 | REPLICATION-DEFICIENT ADENOVIRUS | ALLEN, MICHAEL D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18007364 | REPLICATION-DEFICIENT ADENOVIRUS | ALLEN, MICHAEL D | — |
| 17995728 | METHOD FOR PREDICTING THE COURSE OF A VIRAL DISEASE | ZOU, NIANXIANG | — |
| Art Unit | Apps |
|---|---|
| 1671 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18007364 | REPLICATION-DEFICIENT ADENOVIRUS | ALLEN, MICHAEL D | 1671 | §101§102§103§112 | Non-Final OA | — | Pending | Jan 30, 2023 |
| 17995728 | METHOD FOR PREDICTING THE COURSE OF A VIRAL DISEASE | ZOU, NIANXIANG | 1671 | §103 | Non-Final OA | — | Pending | Oct 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLeibniz-Institut Für Virologie has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Michael D Allen has the most, with 1 of Leibniz-Institut Für Virologie's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
